On May 19, 2026, Bristol Myers Squibb and Pfizer's Eliquis lost European market exclusivity.
Eliquis is the second highest selling drug in the world. It generated 82.6 billion dollars in cumulative revenue since 2011 and was forecast to peak at 14.2 billion dollars in 2025. By 2030, analysts forecast its sales to plummet 92.3 percent.
This is the first major fall in a sequence. The largest revenue compression event in modern pharmaceutical history is already in motion, and most boards have not yet internalized the scale.
The Number
Between 2025 and 2030, between 200 and 400 billion dollars in global branded pharmaceutical revenue will lose patent exclusivity. The most widely cited industry figure is approximately 300 billion dollars, roughly one sixth of total industry annual revenue.
Nearly 200 branded drugs will lose exclusivity in that window. Among them, 69 to 70 blockbusters generating over 1 billion dollars in annual sales each. By 2026, eight of the thirteen largest pharma firms, representing 55 percent of global market value, face 30 percent or more of their revenue at risk. Five of the top ten face greater than 50 percent exposure.
This is not a portfolio level adjustment. For half of large cap pharma, it is an existential repositioning event.
The Four Anchors
Four drugs alone illustrate the scale.
Keytruda. Merck's pembrolizumab generated 29.5 billion dollars in 2024 revenue, approximately 56 percent of Merck's total business. Its core US composition of matter patent expires in 2028. Without effective lifecycle management, analysts project up to 80 percent revenue erosion. Merck's response was to launch Keytruda Qlex, a subcutaneous formulation approved in September 2025, designed to convert 30 to 40 percent of US patients to a defended formulation before biosimilars arrive.
Eliquis. Bristol Myers Squibb and Pfizer's apixaban lost EU exclusivity on May 19, 2026. US exclusivity extends through 2028 to 2029 under formulation and settlement terms. From a 14.2 billion dollar 2025 peak, sales are forecast to fall 92.3 percent by 2030.
Stelara. Johnson and Johnson's ustekinumab generated 10 billion dollars in 2024 and began losing patent protection in 2026. Biosimilars are already entering major markets.
Eylea. Bayer and Regeneron's aflibercept generated 5.9 billion dollars in 2023 and is among the biologics now in second wave biosimilar litigation alongside Stelara.
Together, just these four molecules represent over 60 billion dollars of annual revenue moving through the patent cliff window.
The Long Tail: Ozempic and the GLP-1 Cliff
The cliff does not end in 2030.
Novo Nordisk's semaglutide, sold as Ozempic, Rybelsus, and Wegovy, has its core compound patent expire on December 5, 2031. The practical US generic entry date is 2032. By that date, the GLP-1 category is forecast to be the largest single revenue category in pharma history.
Generic competition for semaglutide will reshape obesity and diabetes pricing structurally. Eli Lilly's tirzepatide enjoys a slightly later runway, but the broader GLP-1 cliff is already on every pharma CFO's planning horizon.
Why This Cliff Is Different
Patent cliffs are not new. Lipitor in 2011. Plavix in 2012. Humira in 2023. What makes the 2025 to 2030 cliff structurally different is the composition.
Most prior patent cliffs were dominated by small molecule drugs. Small molecules face a fast and brutal erosion curve: generic competition typically removes 90 percent of branded revenue within months of loss of exclusivity. The financial shock is severe but predictable.
This cliff is dominated by biologics. Keytruda, Stelara, Eylea, and many of the other expiring blockbusters are biologic products manufactured from living cells. Biologic erosion curves are different. Biosimilars typically erode 30 to 70 percent of branded revenue in the first year and continue grinding for several years after.
The implications for pharma planning are significant. The drop is slower but longer. The defended pricing window is larger but contested every year. The lifecycle management strategies that worked for small molecules, such as authorized generics and reformulation, do not work the same way for biologics.
The pharma boards that built their cliff response playbook from the Lipitor era are running a strategy for the wrong cliff.
The Strategic Response
Three categories of response are visible across large cap pharma.
The reformulation play. Merck's Keytruda Qlex is the leading example. Convert a meaningful share of the patient base to a defended formulation, ideally protected by a separate patent estate, before biosimilars launch. The risk is that the FDA, EMA, and payers are increasingly skeptical of pure lifecycle defense maneuvers, particularly those framed as product hopping.
The acquisition play. Buy revenue. The M and A environment in 2025 was dominated by mid cap and late stage clinical bolt ons designed to replace expiring revenue. The risk is that quality targets are scarce and prices are elevated.
The platform play. Lilly's tirzepatide is the case study. Build a vertically deep franchise around a single molecular platform that can carry a decade of revenue growth on its own. The risk is concentration: if the platform thesis breaks, there is no portfolio breadth to fall back on.
Most of large cap pharma is attempting some combination of all three. The companies that execute one of them well will outperform.
What Pharma Boards Should Be Doing Now
Three questions every pharma board should be answering with precision in 2026.
What percentage of our 2030 revenue is at risk from loss of exclusivity, and what is our defended floor? Most boards have the first number. Few have a credible second number.
What is the realistic erosion curve for each of our biologic franchises facing biosimilar entry? Industry averages are not enough. Brand specific scenarios are now table stakes.
What does our 2030 portfolio look like if our top three replacement assets fail in Phase 3? This is the scenario most pharma board decks do not model honestly.
The pharma companies that answer these three questions with rigor will navigate the cliff. The ones that anchor on industry averages and best case lifecycle management will not.
The Implication
A 300 to 400 billion dollar revenue compression event over five years is not a market dynamic. It is an industry restructuring.
It will reshape M and A pricing, R and D allocation, manufacturing footprint, and commercial organizational design across every major pharma company. It will accelerate the consolidation of mid cap pharma into either large cap or specialty. It will create the conditions for the next decade of platform driven valuations like Lilly's.
The patent cliff is not a future risk. As of today, May 19, 2026, the first big domino has fallen.
The rest is timing.
